Comparison of 14-day versus 21-day tipifarnib administration
| . | 14 days (A) . | 21 days (B) . | P . |
|---|---|---|---|
| Toxicity, no. (%) of patients | |||
| Grade 3 mucositis | 2/54 (4) | 4/30 (13) | .18 |
| Induction death | 3/54 (6) | 6/30 (20) | .06 |
| Efficacy, day to begin cycle 2, median (range) | 30 (29-43) | 35 (29-46) | |
| Complete remission, no. (%) of patients | 16/54 (30) | 5/30 (17) | .29 |
| . | 14 days (A) . | 21 days (B) . | P . |
|---|---|---|---|
| Toxicity, no. (%) of patients | |||
| Grade 3 mucositis | 2/54 (4) | 4/30 (13) | .18 |
| Induction death | 3/54 (6) | 6/30 (20) | .06 |
| Efficacy, day to begin cycle 2, median (range) | 30 (29-43) | 35 (29-46) | |
| Complete remission, no. (%) of patients | 16/54 (30) | 5/30 (17) | .29 |